title: Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
abstract: OBJECTIVE
  This study sought to determine if amantadine affects weight gain in psychiatric patients taking olanzapine.
  
  
  METHODS
  Twenty-one adults who had gained at least 5 lb with olanzapine were randomly assigned to receive amantadine (N=12) or placebo (N=9) in addition to olanzapine. The length of time taking olanzapine ranged from 1 to 44 months. Body mass index, psychiatric status, and fasting blood levels were assessed at baseline and 12 weeks.
  
  
  RESULTS
  Significantly fewer subjects taking amantadine gained weight, with a mean change in body mass index of -0.07 kg/m2 for the amantadine group and 1.24 kg/m2 for the placebo group. This effect remained significant when the authors controlled for baseline body mass index and length of olanzapine treatment. No changes in fasting glucose, insulin, leptin, prolactin, and lipid levels were seen. Positive and Negative Syndrome Scale scores remained stable.
  
  
  CONCLUSIONS
  Amantadine induced weight stabilization in subjects taking olanzapine and was well tolerated.
authors.affiliation: Department of Psychiatry, CB 7160, UNC Neurosciences Hospital, Chapel Hill, NC 27599-7160, USA. karen_graham@med.unc.edu
authors.forename: Karen A
authors.initials: KA
authors.lastname: Graham
authors.forename: Hongbin
authors.initials: H
authors.lastname: Gu
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lieberman
authors.forename: Joyce B
authors.initials: JB
authors.lastname: Harp
authors.forename: Diana O
authors.initials: DO
authors.lastname: Perkins
mesh_terms: D000547:Amantadine / Q000494:pharmacology / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D015259:Dopamine Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced* / Q000188:drug therapy*; D000077152:Olanzapine; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D015259:Dopamine Agents; D010919:Placebos; D001569:Benzodiazepines; D000547:Amantadine; D000077152:Olanzapine